Payment overview · 2025
General Payments
$461.36
25 reported records · 11 companies
Healthcare provider profile · identity verified
Kenneth Brian Goldstein, MD.
Allopathic & Osteopathic Physicians|Internal Medicine · MT. LAUREL, NJ · NPI 1659473239
Verified facts
What the public records show
CMS Open Payments records show Kenneth Brian Goldstein, MD. received $461.36 in general payments during 2025 across 25 reported records.
Exact Sciences Corporation accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Paxlovid, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $103.23 | 22.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.46 | 17.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.11 | 13.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.31 | 13.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.02 | 7.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.72 | 6.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.17 | 4.6% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.50 | 3.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $16.58 | 3.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.44 | 3.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $15.82 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $461.36 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $97.90 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $75.97 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.31 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.70 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.72 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 402 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 20 |
| Famotidine | Famotidine | 130 | 36 |
| Lisinopril | Lisinopril | 120 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 36 |
| Donepezil Hcl | Donepezil Hcl | 115 | 12 |
| Eliquis | Apixaban | 98 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 29 |
| Metformin Hcl | Metformin Hcl | 91 | 22 |
| Losartan Potassium | Losartan Potassium | 89 | 22 |
| Furosemide | Furosemide | 86 | 25 |
| Levetiracetam | Levetiracetam | 82 | 11 |
| Carvedilol | Carvedilol | 78 | 15 |
| Tramadol Hcl | Tramadol Hcl | 73 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 25 |
| Montelukast Sodium | Montelukast Sodium | 65 | 14 |
| Atenolol | Atenolol | 62 | 14 |
| Gabapentin | Gabapentin | 61 | 21 |
| Potassium Chloride | Potassium Chloride | 61 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 18 |
| Omeprazole | Omeprazole | 57 | 18 |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 15 |
| Alprazolam | Alprazolam | 50 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 14 |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Lorazepam | Lorazepam | 46 | 17 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Allopurinol | Allopurinol | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 15 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 12 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 25 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Lubiprostone | Lubiprostone | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 11 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 12 |
| Cephalexin | Cephalexin | 29 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | suppressed |
| Azithromycin | Azithromycin | 25 | 18 |
| Ketoconazole | Ketoconazole | 25 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Valsartan | Valsartan | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $461.36 · 25 records | Exact Sciences Corporation | ABRYSVO, AIRSUPRA, APTIMA, Belbuca, COMIRNATY, Cologuard Collection Kit, FARXIGA, Korlym, OPSUMIT, PAXLOVID, PREVNAR 20, REXULTI, The Cologuard Plus Collection Kit, UPTRAVI, Wegovy, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error